From Compounded to Branded: How a $149 Pill Is Drawing Patients Back to Novo Nordisk as Competitors Close In

Patients shift to branded oral Wegovy at $149/month as FDA restricts compounders. Eli Lilly's retatrutide shows 28.3% weight loss, while Canada opens generic semaglutide market.

A quiet shift is underway in the US weight-loss market. Nine physicians report that patients are abandoning compounded GLP-1 preparations for branded oral alternatives, and Novo Nordisk is the primary beneficiary. The Danish drugmaker's lowest-dose oral Wegovy tablet costs $149 per month under the self-pay model — a price point that sits close to many copycat products and well below the injectable versions. Higher doses range from $199 to $299, depending on supply terms via NovoCare. The pattern suggests that a deliberate pricing strategy is beginning to pull customers back into regulated channels.

The regulatory environment is amplifying that momentum. Late last month, the US Food and Drug Administration proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulk ingredient list. The move would restrict large-scale compounding of those molecules by contract manufacturers, arguing that branded supply is now sufficient to meet clinical demand. For Novo Nordisk, that means less legal competition from unregulated alternatives at a time when trust in the brand remains high. The company's Wegovy franchise benefits from established cardiovascular protection data that newer entrants like Eli Lilly's Foundayo cannot yet match.

Yet the competitive picture is far from serene. On the same day the FDA proposal emerged, Lilly unveiled stunning topline results from the TRIUMPH-1 Phase 3 study of retatrutide, a triple hormone receptor agonist. Patients receiving the highest dose lost an average of 28.3% of their body weight over 80 weeks, with some individuals exceeding 30% — reductions previously reserved for bariatric surgery. Once approved, retatrutide could rewrite the standard of care in obesity and unseat semaglutide-based products as the market benchmark.

Canada, meanwhile, has already opened a generics front. Novo Nordisk's Canadian patent on semaglutide expired earlier than expected — in August 2020, following a missed maintenance fee payment. Health Canada authorised generic versions from Dr. Reddy's in April and from Apotex in May of 2026. That makes Canada the first G7 country with an approved semaglutide generic, and Hims & Hers has already listed the product on its platform. The fallout is another reminder that Novo Nordisk faces threats not only from innovative rivals but also from patent cliffs.

To counter these pressures, the company is turning to artificial intelligence. In April, Novo Nordisk formed a strategic partnership with OpenAI to deploy machine learning across its entire value chain — from early drug discovery through manufacturing to commercialisation. The goal is to shorten development timelines, improve decision-making and accelerate time to market. The initiative signals that management is looking beyond the immediate pricing wars to build longer-term competitive advantages.

Financially, the group remains robust despite the headwinds. First-quarter net sales reached approximately 96.8 billion Danish kroner, with operating profit of 59.6 billion kroner. The full-year 2026 outlook was revised to show revenue growth of minus 4% to minus 12% at constant exchange rates — a wide band that leaves room for operational improvement. More than two million prescriptions have been written for the oral Wegovy pill so far, with roughly 207,000 new scripts added each week.

Shares closed at €38.26, a decline of roughly 14% since the start of the year and 45% below the 52-week high of €70.13. The stock has recovered about 10% above its 50-day moving average after touching a March trough of €30.48. The rebound suggests investors are pricing in a potential strategic inflection point — but the durability of that recovery will depend on how quickly Lilly's retatrutide reaches the market and whether Novo Nordisk can defend its pricing power in the US against both generics and compounders.

The central question for the company now is whether the early gains from oral Wegovy will translate into persistent, high-margin prescriptions. The low entry price is a calculated risk: it lowers the barrier for patients to start, but also depresses average revenue per user. If the patient migration from compounded products proves durable, Novo Nordisk may win back market share without sacrificing its brand premium. If not, the squeeze from Lilly's blockbuster data and Canadian generics will only tighten.